Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% — $190.7 million against Wall Street’s $206-$208 million — and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) — Wall Street modeled roughly $206 million to $208 million in second quarter revenue for Myriad Genetics (NASDAQ: MYGN). The Company reported approximately $190.7 million — a miss of 7% to 8% and a decline of about 11% year over year — and MYGN shares sold off. If you lost money on Myriad Genetics stock, click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Q2 2026 revenue also declined sequentially from the prior quarter. Myriad Genetics reported Q1 2026 revenue of $200.4 million, compared with Q2 2026 revenue of approximately $190.7 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance. The Company also reported a wider-than-expected adjusted loss and lower gross margins for the period.
Alongside the miss, full-year 2026 revenue guidance was reduced to $770 million to $790 million from approximately $860 million to $880 million — roughly $90 million at the midpoint — and full-year adjusted gross margin expectations were lowered. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.
Investors who purchased Myriad Genetics shares and suffered losses are encouraged to have their claim evaluated at no cost, or contact Joseph E. Levi, Esq. at (212) 363-7500.
ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the MYGN Investigation
Q: How much did MYGN stock drop? A: Myriad Genetics shares declined after the Company reported approximately $190.7 million in Q2 2026 revenue against consensus of roughly $206-$208 million and reduced full-year revenue guidance by about $90 million at the midpoint. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Myriad Genetics made materially false or misleading statements regarding its 2026 revenue outlook and the reimbursement, collections, and prenatal testing trends underlying it. When the Company reported the revenue miss and cut guidance, the stock price declined.
Q: Who is eligible to participate in the MYGN investigation? A: Investors who purchased MYGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do MYGN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my MYGN shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought MYGN and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis — no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
